CLINICAL TRIALS PROFILE FOR AMINOGLUTETHIMIDE
✉ Email this page to a colleague
All Clinical Trials for Aminoglutethimide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00006371 ↗ | A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer | Terminated | Janssen Pharmaceuticals | Phase 2 | 2000-05-01 | RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate cancer. |
| NCT00006371 ↗ | A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer | Terminated | National Cancer Institute (NCI) | Phase 2 | 2000-05-01 | RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate cancer. |
| NCT00006371 ↗ | A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer | Terminated | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | 2000-05-01 | RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate cancer. |
| NCT00134680 ↗ | Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC | Completed | Genentech, Inc. | Phase 2 | 2000-01-01 | The purpose of the study is to investigate the effects (good and bad) that the combination of the drugs letrozole (also called Femara™) and trastuzumab (also called Herceptin®) has on breast cancer. The United States (US) Food and Drug Administration has approved both letrozole and Herceptin for the treatment of advanced breast cancer. Doctors hope that the combination will work better than either drug alone. |
| NCT00134680 ↗ | Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC | Completed | Novartis Pharmaceuticals | Phase 2 | 2000-01-01 | The purpose of the study is to investigate the effects (good and bad) that the combination of the drugs letrozole (also called Femara™) and trastuzumab (also called Herceptin®) has on breast cancer. The United States (US) Food and Drug Administration has approved both letrozole and Herceptin for the treatment of advanced breast cancer. Doctors hope that the combination will work better than either drug alone. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Aminoglutethimide
Condition Name
Clinical Trial Locations for Aminoglutethimide
Trials by Country
Clinical Trial Progress for Aminoglutethimide
Clinical Trial Phase
Clinical Trial Sponsors for Aminoglutethimide
Sponsor Name
